Drug Class Prior Authorization Criteria Immune Globulins
|
|
- Lesley Farmer
- 5 years ago
- Views:
Transcription
1 Drug Class Prior Authorization Criteria Immune Globulins Line of Business: Medicaid P & T Approval Date: August 16, 2017 Effective Date: August 16, 2017 This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics Subcommittee. Drugs Requiring Prior Authorization Review: Bivigam, Carimune, Flebogamma, Gammagard, Gammaked, Gammaplex, Gamunex C, Octagam, Privigen (immune globulin), Cubitru, Hizentra (immune globulin, subcutaneous) FDA Approved Indications for IVIG products (CBER): Brand PID CLL ITP Kawasaki Syndrome CIDP Multifocal Motor Neuropathy Bivigam Carimune NF Flebogamma DIF Gammagard Liquid Gammagard S/D Gammaked Gammaplex Gamunex C Hizentra (SCIG) Hyqvia (SCIG) Octagam Privigen PID = primary immune deficiency, CLL = chronic lymphocytic leukemia, ITP = idiopathic thrombocytopenic purpura, CIDP = chronic inflammatory demyelinating polyneuropathy 1. Due to the various dosage forms and adverse events profile IVIG products will be covered based on approved indications after failure of first line treatment options (For detailed criteria please see section: Criteria) a. Approvable non FDA approved indications or off label indications where anecdotal evidence has shown efficacy and where clinical trials may not be appropriate due to rarity of the disease or ethics: Guillain Barre syndrome, dermatomyositis, bone marrow transplantation, and Lambert Eaton Syndrome. b. Other non FDA approved indications ( off label condition) will be reviewed and considered based on evidence for efficacy. Use for the non FDA approved indication must be found in at least one pharmaceutical compendium: United States Pharmacopeia Drug 1 P age
2 Information (USPDI), Drug Information for Healthcare Professional, American Hospital Formulary Service (AHFS) Drug Information, or Micromedex DrugDex. The Clinical Review process will also consider information submitted by the prescriber supporting the intended off label use in the form of two supporting journal articles from nationally recognized peer reviewed journals (e.g. New England Journal of Medicine) or if the use is endorsed by the Local Coverage Determination per CMS. 2. Lab Tests/Monitoring Parameters: a. Baseline renal (BUN & Creatinine Clearance) b. Platelets and Hgb levels c. Immunoglobulin levels (Ig) d. IgA deficiency or IgA antibodies Criteria: 1. Primary Immunodeficiency Syndrome (PID) a. For patients with a primary immunodeficiency syndrome, including the following: i. Hereditary hypogammaglobulinemia ii. Immunodeficiency with increased immunoglobulin M (IgM) iii. Severe combined immunodeficiency (SCID) iv. Major histocompatibility complex deficiency v. Combined immunodeficiency, unspecified vi. Wiskott Aldrich syndrome vii. Common variable immunodeficiency with predominant abnormalities of B cell numbers and function b. Individuals with agammaglobulinemia or hypogammaglobulin i. IgG levels are less than 200mg/dl c. Duration of Prior Authorization: Re evaluate every 6 months d. Confirmed CCS eligibility for age< Idiopathic Thrombocytopenic Purpura (ITP) a. For patients with idiopathic thrombocytopenic purpura (ITP) who meet one of the following: i. To increase platelet count prior to surgery ii. To control excessive bleeding or symptomatic thrombocytopenia iii. To defer or avoid splenectomy iv. Platelet count at or below 30,000/mm3 b. Duration of Prior Authorization: Re evaluation every 6 months c. Confirmed CCS eligibility for age< Idiopathic Thrombocytopenic Purpura (ITP) in Pregnancy a. IVIG will be approved in any one of the following: i. Pregnant women who have previously delivered infants with autoimmune thrombocytopenia ii. Pregnant women who have platelet counts less than 75,000/mm3 during the current pregnancy iii. Pregnant women with a past history of splenectomy 2 P age
3 b. Duration of Prior Authorization: Duration of the pregnancy c. Confirmed CCS eligibility for age< Kawasaki Disease (Mucocutaneous Lymph Node Syndrome) a. Confirmed diagnosis of Kawasaki Disease b. Duration of Prior Authorization: Re evaluate every month 5. B cell Chronic Lymphocytic Leukemia (CLL) a. Confirmed diagnosis of Chronic Lymphocytic Leukemia b. One of the following: i. Documented hypogammaglobulinemia (IgG < 600 mg/dl) ii. evidence of specific antibody deficiency and presence of repeated bacterial infections c. Duration of Prior Authorization: Re evaluate every 6 months 6. Acute or Chronic Inflammatory Demyelinating Neuropathy a. Confirmed diagnosis of acute or chronic inflammatory demyelinating neuropathy b. Duration of Prior Authorization: Re evaluate every 3 months 7. Bone Marrow Transplantation a. Confirmed allogeneic bone marrow transplant b. Documented hypogammaglobulinemia (IgG < 400 mg/dl) or Cytomegalovirus (CMV) seropositive c. Duration of Prior Authorization: Re evaluate every month 8. Dermatomyositis and Polymyositis a. Confirmed diagnosis of dermatomyositis or polymyositis. b. One of the following is met: i. Failure or intolerance to one of the following: corticosteroid therapy, methotrexate, azathioprine, or cyclophosphamide ii. Rapidly progressive form of the disease c. Duration of Prior Authorization: Re evaluate every 3 months 9. Multifocal Motor Neuropathy (MMN) a. Confirmed diagnosis of MMN b. Failure of or contraindications to other therapy c. Rapidly progressive form of the disease d. Duration of Prior Authorization: Re evaluate every 3 months 10. Guillain Barre Syndrome a. Confirmed diagnosis of Guillain Barre Syndrome b. One of the following scenarios is present: i. Failure of or contraindications to other therapy ii. Rapidly progressive form of the disease c. Duration of Prior Authorization: Re evaluate every 3 months 11. Lambert Eaton Myasthenic Syndrome a. Failure of or contraindications to other therapy, and rapidly progressive form of the disease b. Clinical record must document medical necessity to initiate IVIG therapy and the ongoing need as long as treatment continues. 3 P age
4 c. Re authorization: Quantitative monitoring and documented improvement with therapy d. Duration of Prior Authorization: Re evaluate every 3 months 12. Acute Myasthenia Gravis Exacerbation a. Confirmed diagnosis of myasthenia gravis b. Documented significant limiting symptoms that affect one of the following: i. Difficulty swallowing ii. Speech iii. Respiration iv. Motor function (limit physical activity) c. And one of the following i. Failed contraindicated or intolerant to an immunomodulator therapy (e.g. azathioprine, mycophenolate, cyclosporine, corticosteroids, etc.) ii. Concurrently receiving an immunomodulator therapy d. Duration of Prior Authorization: Re evaluate every 6 months 13. Solid organ transplant recipients at risk for infections (e.g. cytomegalovirus infection, pneumonia etc.) a. Duration of Prior Authorization: Re evaluate every 6 months 14. Autoimmune retinopathy a. Limited to three months unless there is improvement on therapy 15. Immune neutropenia a. Duration of Prior Authorization: Re evaluate every 6 months 16. Multiple Myeloma a. Confirmed diagnosis of Multiple Myeloma b. Failure of or contraindications to other therapy, and rapidly progressive form of the disease c. Clinical record must document medical necessity to initiate IVIG therapy and the ongoing need as long as treatment continues. d. Duration of Prior Authorization: Re evaluation every 6 months 17. Symptomatic Human Immunodeficiency Virus (HIV) a. CD4+ lymphocyte counts greater than or equal to 200/mm 3 b. Clinically symptomatic or asymptomatic, but immunologically abnormal c. Confirmed CCS eligibility for age < Autoimmune mucocutaneous blistering diseases a. Confirmed diagnosis of autoimmune bullous disease or one of the following: i. Pemphigus vulgaris ii. Pemphigus foliaceus iii. Bullous pemphigoid iv. Mucous membrane pemphigoid or Cicatrical pemphigoid v. Epidermolysis bullosa acquisita b. And one of the following i. Failed, intolerant or contraindicated to systemic corticosteroids and an immunosuppressive agent (e.g. cyclophosphamide, azathioprine, mycophenolate mofetil etc.) 4 P age
5 ii. Rapidly progressive disease in which a clinical response could not be affected quickly enough using conventional agents. IVIG must be given concomitantly with conventional immunosuppressive agents until conventional therapy take effect. c. Duration of Prior Authorization: Re evaluate every 6 months Common Dosing Range (dosing will vary between products, please refer to FDA approved label, the following recommendations is not all inclusive): 1) Primary Immunodeficiency Syndrome a) Carimune NF: mg/kg IV every 3 to 4 weeks b) Flebogamma, Gammagard Liquid, Gammagard S/D, Gamunex C, or Gammaked: mg/kg IV every 3 to 4 weeks c) Privigen: mg/kg IV every 3 to 4 weeks d) Gammaplex or Bivigam: mg/kg IV every 3 to 4 weeks e) Please refer to FDA labeled dosing for specific subcutaneous immune globulin products 2) Idiopathic Thrombocytopenic Purpura a) Carimune NF: 0.4 g/kg IV daily for 2 5 consecutive days i) In acute ITP of childhood, if an initial platelet count reaches 30 50,000/μL after the first two doses, therapy may be discontinued after the second day of the 5 day course ii) In adults and children, if after induction therapy the platelet count falls to less than 30,000/μL and/or the patient manifests clinically significant bleeding, 0.4 g/kg may be given as a single infusion. If an adequate response does not result, the dose can be increased to g/kg given as a single infusion. b) Gammagard S/D: 1 g/kg IV; up to three separate doses may be given on alternate days if required c) Gamunex C or Gammaked: 1 g/kg/day IV for two consecutive days, or 0.4 g/kg/day IV for five consecutive days i) If after administration of the first 1 g/kg dose, an adequate increase in the platelet count is observed at 24 hours, the second dose may be withheld d) Privigen, Gammaplex, or Octagam: 1g/kg IV daily for 2 consecutive days 3) Chronic Inflammatory Demyelinating Polyneuropathy a) Gamunex C or Gammaked: i) Initial dose: 2 g/kg IV in divided doses over two to four consecutive days ii) Maintenance: 1 g/kg IV over 1 day or 0.5 g/kg/day IV given on two consecutive days, every 3 weeks 4) Kawasaki Disease a) Gammagard S/D: One dose of 1 g/kg IV, or 400 mg/kg/day for four days beginning within 7 days of fever onset, administered concomitantly with appropriate aspirin therapy (80 100mg/kg/day in four divided doses) is recommended 5) Chronic Lymphocytic Leukemia a) Gammagard S/D: 400 mg/kg IV every 3 to 4 weeks 6) Multifocal Motor Neuropathy 5 P age
6 a) Gammagard Liquid: g/kg/month based on clinical response b) Initial dose*: 400 mg/kg IV for 2 5 days or 1 g/kg/day for 2 days c) Maintenance dose*: 1 2 g/kg IV every 4 8 weeks, titrated based on clinical response and symptoms 7) Bone Marrow Transplant* a) Prevention of bacterial infections during the first 100 days after HCT with severe hypogammaglobulinemia (IgG < 400mg/dL): 500 mg/kg/week b) Prevention of bacterial infections beyond 100 days post HCT with severe hypogammaglobulinemia (IgG < 400mg/dL) i) 500mg/kg every 3 4 weeks 8) Dermatomyositis* a) 2 g/kg IV divided over two to five days, every month for three months 9) Guillain Barre Syndrome* a) 400 mg/kg/day IV for 5 days or 1 g/kg daily for 2 days 10) Lambert Eaton Myasthenic Syndrome* a) 2 g/kg IV divided over two consecutive days 11) Myasthenia Gravis Exacerbation* a) 400 mg/kg/day IV for 5 days 12) Bacterial infection in children infected with HIV* a) 400mg/kg given every 28 days 13) Autoimmune bullous diseases* a) 400mg/kg/day for 5 days per month or mg/kg per month divided into 3 equal doses over 3 days * Suggested dosing for off label indications is based on clinical trial data. Change Control Date Change RPH 06/29/2018 Changed Format IK 08/16/2017 Renewed with no updates/changes 6 P age
IMMUNE GLOBULIN (IVIG AND SCIG) Brand Name Generic Name Length of Authorization Bivigam IVIG Per Medical Guidelines Carimune IVIG Per Medical
Brand Name Generic Name Length of Authorization Bivigam IVIG Per Medical Guidelines Carimune IVIG Per Medical Guidelines Flebogamma IVIG Per Medical Guidelines Gammagard IVIG/SCIG Per Medical Guidelines
More informationImmune Globulins Drug Class Prior Authorization Protocol
Line of Business: Medi-Cal Effective Date: May 18, 2016 Renewal Date: August 16, 2017 Immune Globulins Drug Class Prior Authorization Protocol This policy has been developed through review of medical literature,
More informationPrimary Diagnosis: Diagnosis Code(s) (if known): Individual s Weight (lbs) (kg)
Request Date: Initial Request Buy and Bill Individual s Name: Insurance Identification Number: Subsequent request Date of Birth: Individual s Phone Number: Primary Diagnosis: Diagnosis Code(s) (if known):
More informationImmune Globulin. Prior Authorization
MB9423 Covered Service: Yes when meets criteria below Prior Authorization Required: Additional Information: Yes as shown below Requires prior authorization through Navitus and is considered medically appropriate
More informationImmune Globulins. Subcutaneous Immune Globulin: Cuvitru, Hizentra and HyQvia
Immune Globulins Intravenous Immune Globulin (IVIG): Bivigam, Carimune NF, Flebogamma DIF, Gammagard Liquid, Gammagard S/D, Gammaked, Gammaplex, Gamunex-C, Octagam, and Privigen Subcutaneous Immune Globulin:
More informationIntravenous Immune Globulins (IVIG)
Intravenous Immune Globulins (IVIG) Intravenous Immune Globulin (IVIG): Bivigam, Carimune NF, Flebogamma DIF, Gammagard Liquid, Gammagard S/D, Gammaked, Gammaplex, Gamunex-C, Octagam, and Privigen Subcutaneous
More informationIVIG (intravenous immunoglobulin) Bivigam, Carimune NF, Flebogamma, Gammagard, Gammagard S/D, Gammaked, Gammaplex, Gamunex-C, Octagam, Privigen
Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following documented indications: 1. Primary Immunodeficiency Disease (PID) with ONE of the a. Hypogammaglobulinemia,
More informationImmune Globulin Therapy
Immune Globulin Therapy Policy Number: Original Effective Date: MM.04.015 05/21/1999 Line(s) of Business: Current Effective Date: HMO; PPO 08/26/2011 Section: Prescription Drugs Place(s) of Service: Outpatient
More informationIMMUNE GLOBULIN THERAPY
IMMUNE GLOBULIN THERAPY Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and
More informationImmune Globulin Therapy
Immune Globulin Therapy Policy Number: Original Effective Date: MM.04.015 05/21/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 03/01/2015 Section: Prescription Drugs Place(s) of Service:
More informationIntravenous Immune Globulin (IVIg)
Policy Number Reimbursement Policy IVIG04272010RP Approved By UnitedHealthcare Medicare Reimbursement Policy Committee Current Approval Date 10/08/2014 IMPORTANT NOTE ABOUT THIS REIMBURSEMENT POLICY This
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Immunoglobulin for Parvovirus B19 Infection Reference Number: CP.CPA.90 Effective Date: 11.16.16 Last Review Date: 08.17 Line of Business: Commercial Revision Log See Important Reminder
More informationPOLICIES AND PROCEDURE MANUAL
POLICIES AND PROCEDURE MANUAL Policy: MBP 4.0 Section: Medical Benefit Pharmaceutical Policy Subject: Intravenous Immune Globulin (IVIG) I. Policy: Intravenous Immune Globulin (IVIG) II. Purpose/Objective:
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Immunoglobulin for Bacterial Infection in HIV Positive Children Reference Number: CP.CPA.42 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See
More informationPolicy. Medical Policy Manual Approved: Do Not Implement Until 1/31/19. Intravenous Immune Globulin (IVIG) Therapy
Intravenous Immune Globulin (IVIG) Therapy NDC CODE(S) 59730-6502-XX - Bivigam 5 g protein 59730-6503-XX - Bivigam 10 g protein 44206-0416-XX - Carimune NF 3 g protein 44206-0417-XX - Carimune 6 g protein
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Immune Globulin Effective Date 10/15/2017 Next Review Date.10/15/2018 Coverage Policy Number..5026 Table of Contents Coverage Policy... 1 General Background...
More informationIntravenous Immune Globulins (IVIG)
Intravenous Immune Globulins (IVIG) Intravenous Immune Globulin (IVIG): Bivigam, Carimune NF, Flebogamma DIF, Gammagard Liquid, Gammagard S/D, Gammaked, Gammaplex, Gamunex-C, Octagam, and Privigen Subcutaneous
More informationClinical Policy: Immune Globulins Reference Number: CP.PHAR.103 Effective Date: 08/12 Last Review Date: 09/17 Line of Business: Medicaid
Clinical Policy: Reference Number: CP.PHAR.103 Effective Date: 08/12 Last Review Date: 09/17 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of this policy
More informationClinical Policy: Immune Globulins Reference Number: ERX.SPMN.129
Clinical Policy: Immune Globulins Reference Number: ERX.SPMN.129 Effective Date: 03/14 Last Review Date: 09/16 Revision Log Coding_Implications See Important Reminder at the end of this policy for important
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Immunoglobulin for Paraneoplastic Disorders Reference Number: CP.CPA.89 Effective Date: 11.16.16 Last Review Date: 08.17 Line of Business: Commercial Revision Log See Important Reminder
More informationIVIG Immune Globulin Bivigam, Carimune NF, Flebogamma, Gammagard, Gammagard S/D, Gammaked, Gammaplex, Gamunex-C, Octagam, Privigen
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.20.03 Subject: IVIG Page: 1 of 13 Last Review Date: December 2, 2016 IVIG (intravenous immunoglobulin)
More informationClinical Policy: Eltrombopag (Promacta) Reference Number: ERX.SPA.71 Effective Date:
Clinical Policy: (Promacta) Reference Number: ERX.SPA.71 Effective Date: 10.01.16 Last Review Date: 11.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More information3. Does the patient have a diagnosis of warm-type autoimmune hemolytic anemia?
Pharmacy Prior Authorization AETA BETTER HEALTH FLORIDA IVIG (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax
More informationIMMUNE GLOBULIN (IVIG AND SCIG)
IMMUNE GLOBULIN (IVIG AND SCIG) UnitedHealthcare Community Plan Medical Benefit Drug Policy Policy Number: CS2018D0035X Effective Date: March 1, 2018 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT
More informationIMMUNE GLOBULIN (IVIG AND SCIG)
IMMUNE GLOBULIN (IVIG SCIG) Policy Number: 2017D0035U Effective Date: February 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS... 1 COVERAGE RATIONALE... 2 U.S. FOOD DRUG
More informationImmune Globulin Therapy
PHARMACY / MEDICAL POLICY 8.01.503 Immune Globulin Therapy BCBSA Ref. Policy: 8.01.05 Effective Date: Jan. 1, 2019 Last Revised: Dec. 19, 2018 Replaces: N/A RELATED MEDICAL POLICIES: 5.01.550 Pharmacotherapy
More informationSPECIALTY GUIDELINE MANAGEMENT
POLICY SPECIALTY GUIDELINE MANAGEMENT Intravenous Immune Globulin (IVIG): Bivigam, Carimune NF, Flebogamma DIF, Gammagard Liquid, Gammagard S/D, Gammaked, Gammaplex, Gamunex -C, Octagam, and Privigen I.
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Immune Globulins Reference Number: CP.PHAR.103 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan Coding Implications Revision Log See Important Reminder
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Promacta) Reference Number: CP.PHAR.180 Effective Date: 03.01.16 Last Review Date: 02.18 Line of Business: Commercial, Health Insurance Marketplace, Medicaid Revision Log See Important
More informationApplications of this product for conditions other than those addressed in this policy are considered OFF-LABEL and are not addressed in this policy.
Subject: Intravenous infusion Immune Globulin (IVIg) Original Effective Date: 12/6/2007 Policy Number: MCP-043 Revision Date(s): 4/27/2011;1/22/2013 Review Date(s): 4/27/2011;1/22/2013, 12/16/2015; 3/30/2016;
More informationImmune Globulins Last Review Date: September 13, 2016 Number: MG.MM.PH.17av2 Medical Guideline Disclaimer Definition
Last Review Date: September 13, 2016 Number: MG.MM.PH.17av2 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.CPA.142 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Immunoglobulin for Aneurysm in Kawasaki Syndrome Reference Number: CP.CPA.86 Effective Date: 11.16.16 Last Review Date: 08.17 Line of Business: Medicaid Medi-Cal Revision Log See Important
More informationIVIG (Intravenous Immune Globulin) SCIG (Subcutaneous Immune Globulin)
Phone: (800) 244-6224 Fax: (855) 840-1678 IVIG (Intravenous Immune Globulin) SCIG (Subcutaneous Immune Globulin) Notice: Please be sure to complete this form in its entirety. Missing information makes
More informationImmune Globulin Therapy
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationThe University of Mississippi Medical Center The University of Mississippi Health Care. Pharmacy and Therapeutics Committee Medication Use Evaluation
The University of Mississippi Medical Center The University of Mississippi Health Care Pharmacy and Therapeutics Committee Medication Use Evaluation June 2012 Objective The goal of this medication use
More informationBrand Generic J-Code 1 Billable. Exclusion Criteria. Information and Criteria. Unit
Affinity Health Plan Department Of Pharmacy (Medicaid, Child Health Plus, Family Health Plus, Medicare Part B) **Medications Requiring Authorization under Medical Benefit** Click Here For Medication Authorization
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Intravenous and Subcutaneous Immune Globulin Therapy Page 1 of 100 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Intravenous and Subcutaneous Immune Globulin Therapy
More informationImmunologic Products asdhealthcare.com
Immunologic Products Bivigam Carimune NF Flebogamma DIF Gammagard S/D Low IGA Gammagard Liquid Gammaked Gammaplex Gamunex -C Hizentra HyQvia Octagam Privigen Immunologic Products 800.746.6273 asdhealthcare.com
More informationPOLICY Document for Intravenous Immune Globulin (IVIG)
'-..-Ct.I t.j..l.l ~L..,r. V. Family of health care plans CV$ Caremark POLICY Document for Intravenous Immune Globulin (IVIG) The overall objective of this policy is to support the appropriate and cost
More informationFrom: Plasma Protein Therapeutics Association (PPTA)
Polyvalent Human Immunoglobulins Application for reinstatement to the WHO Model List From: Plasma Protein Therapeutics Association (PPTA) 1. Summary statement of the proposal for inclusion, change or deletion
More informationOriginal Policy Date
MP 8.01.04 Immune Globulin Therapy Medical Policy Section Therapy Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date Reviewed with literature search/12/2013 Return to Medical Policy Index
More informationLocal Coverage Determination (LCD) for Intravenous Immune Globulin (L29205)
Local Coverage Determination (LCD) for Intravenous Immune Globulin (L29205) Contractor Information Contractor Name First Coast Service Options, Inc. Back to Top Contractor Number 09102 Contractor Type
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Intravenous and Subcutaneous Immune Globulin Therapy Page 1 of 68 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Intravenous and Subcutaneous Immune Globulin Therapy
More informationImmune Globulin. Clinical Overview Program BioScrip Inc. All rights reserved BioScrip Inc. All rights reserved.
Immune Globulin Clinical Overview Program Objectives Discuss Autoimmune disorders Describe IG structure, properties and clinical implications Discuss IG product usage, storage and mixing guidelines Discuss
More informationSCIG: (Immune globulin SQ) Hizentra, Vivaglobin, Gammagard Liquid, Gamunex- C, Gammaked, Hyqvia Page 1 of 6
Moda Health Plan, Inc. Medical Necessity Criteria Subject: Origination Date: 04/1 Revision Date(s): 02/16 Developed By: Medical Criteria Committee Effective Date: 0/01/1 SCIG: (Immune globulin SQ) Hizentra,
More informationDRUG USE EVALUATION: OFF-LABEL USE OF IMMUNE GLOBULIN G
G The Immunoglobulin G (IgG) drug class evidence review on products identified strong evidence to support the use of intravenous and subcutaneous IgG for primary immunodeficiency and little evidence preferring
More informationPPO/CDHP: Medical. Coverage Criteria: Express Scripts, Inc. monograph dated 01/13/2010
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: Immune globulin intravenous injection IVIG (Carimune NF; Flebogamma ; Flebogamma DIF; Gammagard Liquid; Gammagard ; Octagam ; Privigen Liquid; Gamunex
More informationSubcutaneous Immune Globulin: Alternative Therapeutic Pathway for Patients With Primary Immunodeficiency
Subcutaneous Immune Globulin: Alternative Therapeutic Pathway for Patients With Primary Immunodeficiency EDUCATIONAL OBJECTIVES Upon completion of this program, participants should be better able to: 1.
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: immune_globulin_therapy 07/1994 2/2017 2/2018 2/2017 Description of Procedure or Service Human immunoglobulin
More informationIntravenous Immune Globulins (immune globulin) Document Number: MODA-0071
Intravenous Immune Globulins (immune globulin) Document Number: MODA-0071 Last Review Date: 09/19/2017 Date of Origin: 07/20/2010 Dates Reviewed: 09/2010, 12/2010, 02/2011, 03/2011, 06/2011, 09/2011, 10/2011,
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: immune_globulin_therapy 07/1994 2/2017 2/2018 2/2017 Description of Procedure or Service Human immunoglobulin
More informationImmune Globulins CG DRUG 09, DRUG.00013
Market DC Immune Globulins CG DRUG 09, DRUG.00013 Override(s) Prior Authorization Medications Intravenous: Gamunex-C Octagam Bivigam Carimune NF Flebogamma DIF Gammagard Liquid Gammagard S/D less IgA Gammaked
More informationDisclosure. IVIg Medication Safety: Facts and Fantasies associated with Use. Goals and Objectives. What is IVIG or IGIV?
IVIg Medication Safety: Facts and Fantasies associated with Use. Jerry Siegel, PharmD, FASHP Clinical Associate Professor, The Ohio State University College of Pharmacy Columbus, Ohio Disclosure I have
More informationDepartment of Origin: Pharmacy. Approved by: Pharmacy and Therapeutics Quality Management Subcommittee Effective Date: Date approved: 11/09/16
Reference #: PC/I002 Page: 1 of 9 PRODUCT APPLICATION: PreferredOne Administrative Services, Inc. (PAS) ERISA PreferredOne Administrative Services, Inc. (PAS) Non-ERISA PreferredOne Community Health Plan
More informationModular Program Report
Modular Program Report The following report(s) provides findings from an FDA initiated query using its Mini Sentinel pilot. While Mini Sentinel queries may be undertaken to assess potential medical product
More informationP&T Committee Meeting Minutes GHP Family March 21, 2017
P&T Committee Meeting Minutes GHP Family March 21, 2017 Present: Bret Yarczower, MD, MBA Chair Dean Christian, MD via phone Kimberly Clark, Pharm.D. Kristi Clarke, Pharm. D. via phone Jamie Dodson, RPh
More informationMEDICAL POLICY IMMUNE GLOBULIN MP POLICY TITLE POLICY NUMBER
Original Issue Date (Created): September 20, 2002 Most Recent Review Date (Revised): June 4, 2013 Effective Date: October 1, 2013 I. POLICY Intravenous Immune globulin (IVIg) Therapy IVIg may be considered
More informationMedical Review Criteria Immune Globulin
Medical Review Criteria Immune Globulin Effective Date: April 13, 2017 Subject: Immune Globulin Authorization: Prior authorization is required for all immune globulin provided to members enrolled in commercial
More informationEvolving Uses of IVIG in myositis
Evolving Uses of IVIG in myositis Rossitza I. Chichkova, MD, MS Associate Professor Depts of Neurology and Internal Medicine University of South Florida, Tampa, FL Immune Function In Normal State: Protects
More informationThrombopoietin Receptor Agonists Prior Authorization with Quantity Limit Program Summary
Thrombopoietin Receptor Agonists Prior Authorization with Quantity Limit Program Summary Thrombopoietin Receptor Agonists Prior Authorization with Quantity Limit OBJECTIVE The intent of the prior authorization
More informationPHARMACY PRIOR AUTHORIZATION. Parenteral Immune Globulins Clinical Guideline
PHARMACY PRIOR AUTHORIZATION Parenteral Immune Globulins Clinical Guideline Bivigam Inj 10% Carimune NF Inj 12gm Carimune NF Inj 3gm Carimune NF Inj 6gm Cuvitru 1g/5mL Cuvitru 2g/10mL Cuvitru 4g/20mL Cuvitru
More informationForm 2033 R3.0: Wiskott-Aldrich Syndrome Pre-HSCT Data
Key Fields Sequence Number: Date Received: - - CIBMTR Center Number: CIBMTR Recipient ID: Has this patient's data been previously reported to USIDNET? USIDNET ID: Today's Date: - - Date of HSCT for which
More informationIntravenous Immunoglobulin (IVIG)*
Subject: Intravenous Immunoglobulin (IVIG)* Updated: December 9, 2008 Department(s): Policy: Objective: Procedure: Utilization Management The use of intravenous immunoglobulin is reimbursable under Plans
More informationCommittee Approval Date: May 9, 2014 Next Review Date: May 2015
Medication Policy Manual Policy No: dru248 Topic: Benlysta, belimumab Date of Origin: May 13, 2011 Committee Approval Date: May 9, 2014 Next Review Date: May 2015 Effective Date: June 1, 2014 IMPORTANT
More informationIntragam P audit within eight centres in New Zealand
Intragam P audit within eight centres in New Zealand Final Report Audit data collated by: Rachel Donegan : Auckland Christopher Corkery : Waikato and Bay of Plenty Anup Chand : MidCentral Fiona King :Capital
More informationClinical Policy Title: Intravenous immunoglobulin
Clinical Policy Title: Intravenous immunoglobulin Clinical Policy Number: 00.02.11 Effective Date: April 1, 2015 Initial Review Date: November 19, 2014 Most Recent Review Date: May 1, 2018 Next Review
More informationPharmacy Medical Necessity Guidelines: Immune Globulin (IVIg, SCIg)
Pharmacy Medical Necessity Guidelines: Immune Globulin (IVIg, SCIg) Effective: September 12, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review
More informationAbbreviated Class Review: Immunoglobulin G. Month/Year of Review: March 2014 End date of literature search: January 1, 2014 PDL Class: None
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationPharmacy Prior Authorization
Pharmacy Prior Authorization AETA BETTER HEALTH PESLVAIA & AETA BETTER HEALTH KIDS Promacta (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review
More informationMechanisms of action of IVIg: What do we really know?
Plasma Protein Biotechnology Meeting 2013, Lanzarote, Spain May 15, 2013 Mechanisms of action of IVIg: What do we really know? Alan H. Lazarus, PhD Canadian Blood Services St. Michael s Hospital University
More informationAppendix to Notification Letter for rituximab and eltrombopag dated 20 February 2014
Appendix to Notification Letter for rituximab and eltrombopag dated 20 February 2014 The notification letter which contains details of the decision to widen the restriction criteria for rituximab and eltrombopag
More informationImmune Globulin Comparison Table
I. Formulation data Gamunex /IGIVnex Gammagard Liquid Privigen Vivaglobin Formulation Lyophilized Liquid Liquid Liquid Liquid Concentration 5% or 10% upon reconstitution Administration set provided? IgA
More informationPharmacy Prior Authorization
Pharmacy Prior Authorization MERC CARE (MEDICAID) Promacta (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax
More informationPROMACTA (eltrombopag olamine) oral tablet and oral suspension
PROMACTA (eltrombopag olamine) oral tablet and oral suspension Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit
More informationPharmacy Management Drug Policy
SUBJECT: Intravenous Immune Globulin (IVIG) & Sub-Cutaneous Immune Globulin (SCIG) Therapy POLICY NUMBER: PHARMACY-26 EFFECTIVE DATE: 11/2005 LAST REVIEW DATE: 10/06/2017 If the member s subscriber contract
More informationCase Management of the Challenging IgG Patient: Clinical Considerations for the Most Effective and Safe Therapy
Case Management of the Challenging IgG Patient: Clinical Considerations for the Most Effective and Safe Therapy By Jerry Siegel, PharmD, FASHP Adapted by Jeannie Counce and Nancy Kramer, RN, BSN, CRNI
More informationCONSUMER MEDICINE INFORMATION LEAFLET
CONSUMER MEDICINE INFORMATION LEAFLET Read all of this leaflet carefully before you start using this medicine. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask
More informationElements for a Public Summary
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Nanogam is intended to be used for the treatment of diseases in patients who are suffering from a shortage of immunoglobulins
More informationSubject: Immune Globulin Therapy
09-J0000-06 Original Effective Date: 12/15/99 Reviewed: 11/14/18 Revised: 12/15/18 Subject: Immune Globulin Therapy THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION OF
More informationOriginal Effective Date: 02/02/15. Subject: Intravenous Immune Globulin (IVIg) Therapy for Solid Organ Transplant. Policy Number: MCP-237
Subject: Intravenous Immune Globulin (IVIg) Therapy for Solid Organ Transplant Policy Number: MCP-237 Original Effective Date: 02/02/15 Revision Date(s): Review Date(s): 12/15/2016; 6/22/2017 DISCLAIMER
More information2. Does the patient have a diagnosis of chronic idiopathic thrombocytopenic purpura (ITP)?
Pharmacy Prior Authorization MERC CARE (MEDICAID) Promacta (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax
More informationΕλένη Ι. Καμπυλαυκά Μέτσοβο, Ιανουάριος 2011
Παθολογική Φυσιολογία Ιατρική Σχολή Ελένη Ι. Καμπυλαυκά Μέτσοβο, Ιανουάριος 2011 Εθνικό & Καποδιστριακό Πανεπιστήμιο Αθηνών Main Principles Pathogenetic Mechanisms Clinical Applications Immunodeficiencies-
More informationONE of the following:
Medical Coverage Policy Belimumab (Benlysta) EFFECTIVE DATE: 01 01 2012 POLICY LAST UPDATED: 11 21 2017 OVERVIEW Belimumab (Benlysta ) is indicated for the treatment of adult patients with active, autoantibody-positive,
More informationModular Program Report
Modular Program Report The following report(s) provides findings from an FDA initiated query using its Mini Sentinel pilot. While Mini Sentinel queries may be undertaken to assess potential medical product
More informationPharmacy Management Desk Level Procedure
Page 1 of 19 DESCRIPTION: Intravenous immune globulin (IVIG) therapy is used to provide antibodies to patients who are susceptible to diseases for which there is no immunization available. IVIG is a potent
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Romiplostim Table of Contents Coverage Policy... 1 General Background... 2 Coding/Billing Information... 4 References... 4 Effective Date... 12/15/2017 Next
More informationReports of efficacy and safety studies of primary immunodeficiency
2. SYNOPSIS TITLE OF STUDY: Clinical Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of IGIV3I GRIFOLS [Immune Globulin Intravenous (Human)] for Replacement Therapy in Primary Immunodeficiency
More informationOmr-IgG-am 5% IV Cleared to Return to Market.
26 July, 2012 Dear Doctor/Pharmacist/Manager, Omr-IgG-am 5% IV Cleared to Return to Market. Omrix Biopharmaceuticals is pleased to inform you that Omr-IgG am 5% IV received clearance from the Israeli Ministry
More informationBenlysta (belimumab) Prior Authorization Criteria Program Summary
Benlysta (belimumab) Prior Authorization Criteria Program Summary This prior authorization applies to Commercial, NetResults A series, NetResults F series and Health Insurance Marketplace formularies.
More informationTreatment pathway for adult patients with immune (idiopathic) thrombocytopenic purpura (ITP)
Prescribing Clinical Network Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath CCG) Crawley and Horsham & Mid-Sussex CCG Treatment pathway for adult
More informationBDI Pharma, LLC 2018 Product Reference Charts
BDI Pharma, LLC 2018 Product Reference Charts Protein Therapies Intravenous Immune Globulin (10%) 800.948.9834 www.bdipharma.com BIVIGAM NF ADMA Biologics Flebogamma 10% DIF GAMMAGARD LIQUID Gammaked Kedrion
More informationThe Role of Anti-D in the Management of Chronic and Secondary Forms of ITP
The Role of Anti-D in the Management of Chronic and Secondary Forms of ITP 473 82 The Role of Anti-D in the Management of Chronic and Secondary Forms of ITP MAURICE GILLES GENEREUX BACKGROUND Immune thrombocytopenic
More informationQUICK REFERENCE Clinical Practice Guideline on the Evaluation and Management of Immune Thrombocytopenia (ITP)
QUICK REFERENCE 2011 Clinical Practice Guideline on the Evaluation and Management of Immune Thrombocytopenia (ITP) Presented by the American Society of Hematology, adapted from: The American Society of
More informationPrivigen solution for infusion
Privigen solution for infusion Haematology Patient Information What is is Privigen? Privigen? Privigen belongs in a class of medicines called human normal immunoglobins. Immunoglobulins are also called
More informationDosing schedules for IVIG: The use of an algorithm as a suggestion for personalized dosing
Dosing schedules for IVIG: The use of an algorithm as a suggestion for personalized dosing 1 Disclosure The presentation contains information outside the labelled indication for intravenous immunoglobulin
More informationeltrombopag (Promacta )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationIntravenous Immune Globulin Toolkit for Ontario
Intravenous Immune Globulin Toolkit for Ontario Central ORBCoN Office 416.480.6100 ext. 89433 Northern and Eastern ORBCoN Office 613.798.5555 ext. 19741 Southwest ORBCoN Office 905.521.2100 ext. 76850
More informationIntravenous immunoglobulin how to use it
DECEMBER 2001 93 THERAPEUTIC INTERVENTION Intravenous immunoglobulin how to use it Jane Pritchard and Richard A.C. Hughes Department of Neuroimmunology, Guy s, King s and St Thomas School of Medicine,
More informationKnow your IVIg options for primary immunodeficiency
Please see full on following page Please see full prescribing information for Privigen, including boxed warning, in pocket. Please see full above See full prescribing information for full boxed warning.
More information